Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR)

The firm is investigating potential claims against the board of directors of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR) concerning whether the board has breached its fiduciary duties to shareholders or violated the federal securities laws.

Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), a Delaware corporation headquartered in Cambridge, Massachusetts, is a biopharmaceutical company that develops and commercializes therapies for patients with debilitating rare diseases in the United States. One of the company’s drugs is JUXTAPID (lomitapide), which is utilized as an adjunct to a low-fat diet and other lipid-lowering treatments in patients with homozygous familial hypercholesterolemia.

On November 8, 2013, the company received an FDA Warning Letter based on comments CEO Marc Beer made on CNBC’s “Fast Money”, which aired on June 5, 2013 and October 31, 2013. The FDA letter stated that Beer’s public statements indicated that Juxtapid was intended for new uses, for which it lacked FDA approval.

On January 10, 2014, the Company received a subpoena from the U.S. Department of Justice requesting documents regarding the marketing and sales of Juxtapid.

If you are aware of any facts relating to this investigation, or are a current shareholder since December 21, 2012 and would like to discuss your options of exercising your rights as a shareholder, please contact us.

Please submit the following information so we can determine if you qualify for the suit. If you don't know all the specific details, partial information is also acceptable.

Personal Information
Phone #:
E-mail Address:
Stock Information
Do you currently own the stock? Yes   No
Purchase Date:
Quantity Purchased:
Purchase Price Per Share:

Please Note: Neither the submission to nor the receipt of information by The Law Offices of Marc S. Henzel or one of its attorneys through this website constitutes an agreement by the firm to represent the individual and does not create an attorney-client relationship.